Last reviewed · How we verify
Klaricid
Klaricid is a Small molecule drug developed by Chang Gung Memorial Hospital. It is currently in Phase 1 development. Also known as: Clarithromycin.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Klaricid |
|---|---|
| Also known as | Clarithromycin |
| Sponsor | Chang Gung Memorial Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
- Diarrhoea
- Dysgeusia
Key clinical trials
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial (NA)
- Antibiotics vs Corticosteroids in Treatment of Granulomatous Lobular Mastitis (PHASE1, PHASE2)
- Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study
- Simplified Dual Regimen Guided by Fecal Clarithromycin Resistance Gene Detection for First-line H. Pylori Eradication (NA)
- Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1 (PHASE4)
- Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy (PHASE4)
- The Impact of Helicobacter Pylori Eradication on the Vaginal Microecology Change
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Klaricid CI brief — competitive landscape report
- Klaricid updates RSS · CI watch RSS
- Chang Gung Memorial Hospital portfolio CI
Frequently asked questions about Klaricid
What is Klaricid?
Who makes Klaricid?
Is Klaricid also known as anything else?
What development phase is Klaricid in?
What are the side effects of Klaricid?
Related
- Manufacturer: Chang Gung Memorial Hospital — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Clarithromycin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing